CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Abbott will add a new FDA-cleared molecular diagnostic test for detection and differentiation of influenza A and B and respiratory syncytial virus to its infectious disease testing menu. The IMDx Flu A/B and RSV test developed by IntelligentMDx (IMDx) of Cambridge, Mass., is performed on Abbott’s m2000 molecular diagnostics system.
Abbott and IMDx announced in 2011 a multiyear distribution agreement through which IMDx designs, develops, and obtains regulatory clearances for real-time PCR assays for the Abbott m2000 instrument system and then manufactures the assays.
The IMDx Flu A/B and RSV test is a qualitative RT-PCR test. It is fully automated, can analyze up to 94 patient samples per run, and is capable of detecting at least 55 strains of influenza A and B and RSV, including variant strains.
Abbott, 224-361-7671